)
Visual21 Nov 2025
Data center suppliers
bioAffinity Technologies (BIAF) investor relations material
bioAffinity Technologies Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
CyPath® Lung testing revenue rose 86% year-over-year to $619,000 for the nine months ended September 30, 2025, with test volumes up 97% over the same period, reflecting strong adoption, especially in Veterans' hospitals and the mid-Atlantic region.
Consolidated revenue declined 36% year-over-year to $4.6 million due to discontinuation of unprofitable pathology services and a strategic focus on CyPath® Lung sales growth.
The company raised $10.4 million in gross proceeds from equity transactions in the current quarter to fund operations and growth initiatives.
Net loss for Q3 2025 was $5.1 million ($4.74 per share), compared to $2.0 million ($4.84 per share) in Q3 2024, mainly due to change in fair value of warrants.
Regained full Nasdaq Capital Market compliance for continued listing, subject to a one-year panel monitor.
Financial highlights
Net revenue for Q3 2025 was $1.45 million, down from $2.35 million in Q3 2024; nine-month revenue was $4.57 million, down from $7.15 million year-over-year.
CyPath® Lung testing revenue increased 122% year-over-year in Q3 2025.
Operating expenses for Q3 2025 were $3.7 million, down from $4.3 million in Q3 2024; nine-month operating expenses were $12.0 million, down from $13.2 million year-over-year.
Cash and cash equivalents as of September 30, 2025, were $7.7 million, up from $1.1 million at the start of the period.
Net loss for the nine months ended September 30, 2025, was $11.8 million, compared to $6.1 million for the same period in 2024.
Outlook and guidance
Management expects current cash resources to support operations through May 2026, but substantial doubt exists about the ability to continue as a going concern beyond that without additional capital.
The company plans to continue expanding commercialization of CyPath® Lung and developing new diagnostic and therapeutic products, requiring further funding.
Strategic actions to streamline operations and reduce costs are expected to support future growth and profitability.
Resource reallocation from pathology services?
What is the scope of the VA longitudinal study?
Impact of warrant fair value on net loss?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next bioAffinity Technologies earnings date
Q4 202531 Mar, 2026
Next bioAffinity Technologies earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
bioAffinity Technologies Inc. is a biotechnology company focused on addressing the critical need for non-invasive, early-stage cancer diagnosis and targeted cancer treatments. The company's flagship product, CyPath Lung, is a diagnostic test for the early detection of lung cancer. Additionally, the company is involved in research and development efforts aimed at creating targeted diagnostics and therapeutics to combat cancer, leveraging its core porphyrin platform technology. The company is headquartered in is headquartered in San Antonio, Texas, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage